Latest advances in neoadjuvant therapy for bladder cancer
Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations f...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | Perú |
| Institución: | Colegio Médico del Perú |
| Repositorio: | Acta Médica Peruana |
| Idioma: | español |
| OAI Identifier: | oai:amp.cmp.org.pe:article/2201 |
| Acceso en línea: | https://amp.cmp.org.pe/index.php/AMP/article/view/2201 |
| Access Level: | acceso abierto |
| Palabra clave: | Neoplasias de la Vejiga Urinaria Terapia Neoadyuvante Inmunoterapia Biomarcadores Urinary Bladder Neoplasms Neoadjuvant Therapy Immunotherapy Biomarkers |
| Sumario: | Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations from international and/or local practice guidelines, as well as studies of new therapeutic agents (immunotherapy, targeted therapy), on top of research on potential biomarkers that may predict response to immunotherapy. |
|---|